Merck Seeks Emergency Use Authorization for Antiviral COVID-19 Treatment Molnupiravir.
Merck and Ridgeback Biotherapeutics
said Monday that it is seeking emergency use authorization for its antiviral treatment, molnupiravir.
from the U.S. Food and Drug Administration.
At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%, Merck, via statement.
During a White House COVID-19
briefing last week, Dr. Anthony Fauci said
the trial results are “very encouraging.”.
It is very important that
this now must go through
the usual process of
careful examination.., Dr. Anthony Fauci, via briefing.
... of the data by the Food and Drug Administration
both for effectiveness,
but also for safety. , Dr. Anthony Fauci, via briefing.
If authorization is granted, it will
be the first oral antiviral treatment
to fight the coronavirus.
The drug comes in capsule form.
The company said that it will
provide tiered pricing so that the drug
will be accessible around the world.
Merck also said it will work with
generic drug manufacturers so
that low- and middle-income
countries will also have access.